Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 4
2021 2
2022 5
2024 4
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.
Lim SY. Lim SY. Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577. Womens Health (Lond). 2022. PMID: 36154750 Free PMC article. Review.
The pivotal ARCH and FRAME studies established romosozumab's fracture reduction efficacy. Romosozumab was superior to alendronate in fracture reduction and bone mineral density gain in the ARCH study. ...The ARCH trial showed a higher ris …
The pivotal ARCH and FRAME studies established romosozumab's fracture reduction efficacy. Romosozumab was superi …
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Miller PD, et al. J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. J Bone Miner Res. 2022. PMID: 35466448 Free PMC article. Clinical Trial.
The present post hoc analysis of two randomized, multicenter, phase 3 clinical trials-Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) and Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk ( …
The present post hoc analysis of two randomized, multicenter, phase 3 clinical trials-Fracture Study in Postmenopausal Women with …
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, Wang Z, Libanati C, Cosman F. Lane J, et al. Osteoporos Int. 2024 Jul;35(7):1195-1204. doi: 10.1007/s00198-024-07049-w. Epub 2024 Apr 4. Osteoporos Int. 2024. PMID: 38573517 Free PMC article. Clinical Trial.
PURPOSE: Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post-fracture period, in the FRAME and ARCH phase 3 trials. METHODS: In FRAME (NCT01575834) and ARCH (NCT01631214), postmenopausal wom …
PURPOSE: Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post-fracture period, in the …
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S. Cosman F, et al. Osteoporos Int. 2022 Jun;33(6):1243-1256. doi: 10.1007/s00198-021-06174-0. Epub 2022 Feb 15. Osteoporos Int. 2022. PMID: 35165774 Free PMC article.
To evaluate whether treatment sequence affects romosozumab response, we reviewed randomized clinical trials where romosozumab was administered before (ARCH, FRAME) or following (STRUCTURE, Phase 2 extension) an antiresorptive (alendronate or denosumab, …
To evaluate whether treatment sequence affects romosozumab response, we reviewed randomized clinical trials where romosozumab …
Romosozumab: A Review in Postmenopausal Osteoporosis.
Paik J, Scott LJ. Paik J, et al. Drugs Aging. 2020 Nov;37(11):845-855. doi: 10.1007/s40266-020-00793-8. Drugs Aging. 2020. PMID: 32909197 Review.
Subcutaneous romosozumab is approved in several countries, including those of the EU for treating severe osteoporosis as well as in the USA for osteoporosis in postmenopausal women at high risk of fracture. In pivotal phase III trials (FRAME and …
Subcutaneous romosozumab is approved in several countries, including those of the EU for treating severe osteoporosis as well …
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.
Chiu SH, Wu WT, Yao TK, Peng CH, Yeh KT. Chiu SH, et al. Biomedicines. 2024 Dec 18;12(12):2880. doi: 10.3390/biomedicines12122880. Biomedicines. 2024. PMID: 39767786 Free PMC article. Review.
Methods: This review synthesizes data from clinical trials, such as ARCH, BRIDGE, and FRAME, alongside genetic studies and observational analyses, to evaluate the cardiovascular safety of romosozumab. ...Results: Romosozumab significantly improves BMD …
Methods: This review synthesizes data from clinical trials, such as ARCH, BRIDGE, and FRAME, alongside genetic studies and obs …
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives.
Lim SY, Bolster MB. Lim SY, et al. Int J Womens Health. 2022 Dec 15;14:1733-1747. doi: 10.2147/IJWH.S315184. eCollection 2022. Int J Womens Health. 2022. PMID: 36544862 Free PMC article. Review.
The FRAME and ARCH studies represent two pivotal trials demonstrating the efficacy of romosozumab in treating osteoporosis. ...Further studies are needed to clarify the increased cardiovascular risk attributed to this drug. Romosozumab has expan …
The FRAME and ARCH studies represent two pivotal trials demonstrating the efficacy of romosozumab in treating osteop …
Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review.
Shakeri A, Adanty C. Shakeri A, et al. J Popul Ther Clin Pharmacol. 2020 Jan 6;27(1):e25-e31. doi: 10.15586/jptcp.v27i1.655. J Popul Ther Clin Pharmacol. 2020. PMID: 31922699 Review.
Romosozumab (ROMO) is a recently approved monoclonal antibody (approved by the U.S. Food and Drug Administration [FDA] in April 2019 and Health Canada in June 2019) for the treatment of osteoporosis in postmenopausal women. ...The authors reviewed three phase …
Romosozumab (ROMO) is a recently approved monoclonal antibody (approved by the U.S. Food and Drug Administration [FDA] in April 2019 …
Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.
Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, Langdahl B, Wang Z, Rojeski M, Libanati C. Geusens P, et al. Bone. 2022 Jan;154:116209. doi: 10.1016/j.bone.2021.116209. Epub 2021 Sep 20. Bone. 2022. PMID: 34547521 Free article. Clinical Trial.
Data are reported from two phase 3 clinical studies for patients who received romosozumab versus placebo through 12 months, followed by denosumab through 24 months (FRAME: NCT01575834), and for patients who received romosozumab through 12 months, followed by …
Data are reported from two phase 3 clinical studies for patients who received romosozumab versus placebo through 12 months, followed …
3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y, Winzenrieth R, Ferrari S, Omura F. Lewiecki EM, et al. J Bone Miner Res. 2024 May 2;39(4):473-483. doi: 10.1093/jbmr/zjae028. J Bone Miner Res. 2024. PMID: 38477808 Free PMC article. Clinical Trial.
Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 yr. ...At month 12, treatment with romosozumab vs placebo in FRA …
Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorpti …
16 results